MediciNova's Archives - World Asthma Foundation

Positive Data on MediciNova’s MN-221 – Analyst Blog – NASDAQ

Positive Data on MediciNova's MN-221 – Analyst Blog
NASDAQ
MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all …
Drug trial signals hope for asthma sufferersSan Diego Source (subscription)
MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat …MarketWatch (press release)
Illinois Investor Commits to Buy MediciNova StockSan Diego Business Journal

all 14 news articles »

MediciNova's MN-166 Program Recognized as One of Windhover's Top 10 …
MarketWatch (press release)
Ibudilast is marketed in Japan and South Korea for the treatment of asthma and cerebrovascular disorders for which MediciNova discovered its potential as a …

and more »